To provide that the final rule of the Department of Health and Human Services titled "Medications for the Treatment of Opioid Use Disorder", except for the portion of the final rule relating to accreditation of opioid treatment programs, shall have no force or effect.
This proposed legislation aims to prevent the implementation of a significant final rule issued by the Department of Health and Human Services (HHS) regarding medications for opioid use disorder. The bill mandates that the HHS final rule, published on February 2, 2024, and titled "Medications for the Treatment of Opioid Use Disorder," shall have no legal force or effect, thereby halting its broader regulatory changes. A key provision of the bill includes an important exception: the portion of the final rule that makes modifications to regulations concerning the accreditation of opioid treatment programs will remain in effect. This ensures that specific updates to accreditation standards are not invalidated by the bill. The overall effect of this bill would be to largely block the new regulatory framework for opioid use disorder medications proposed by HHS, while allowing only the changes pertaining to the accreditation processes for treatment programs to proceed.
Get AI-generated questions to help you understand this bill better
Timeline
Introduced in House
Referred to the House Committee on Energy and Commerce.
Introduced in House
Referred to the House Committee on Energy and Commerce.
Health
To provide that the final rule of the Department of Health and Human Services titled "Medications for the Treatment of Opioid Use Disorder", except for the portion of the final rule relating to accreditation of opioid treatment programs, shall have no force or effect.
USA119th CongressHR-5629| House
| Updated: 9/30/2025
This proposed legislation aims to prevent the implementation of a significant final rule issued by the Department of Health and Human Services (HHS) regarding medications for opioid use disorder. The bill mandates that the HHS final rule, published on February 2, 2024, and titled "Medications for the Treatment of Opioid Use Disorder," shall have no legal force or effect, thereby halting its broader regulatory changes. A key provision of the bill includes an important exception: the portion of the final rule that makes modifications to regulations concerning the accreditation of opioid treatment programs will remain in effect. This ensures that specific updates to accreditation standards are not invalidated by the bill. The overall effect of this bill would be to largely block the new regulatory framework for opioid use disorder medications proposed by HHS, while allowing only the changes pertaining to the accreditation processes for treatment programs to proceed.